Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential

Anti-Cancer Drugs

Volumn 13, Issue 9, 2002, Pages 915-924

  Bouma, M ^a   Nuijen, B ^a   Stewart, D R ^b   Rice, J R ^b   Jansen, B A J ^c   Reedijk, J ^c   Bult, A ^d   Beijnen, J H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b Access Pharmaceuticals Inc   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

AP 5280; Compatibility; Hemolysis; Infusion devices; Stability

Indexed keywords

ANTINEOPLASTIC AGENT; AP 5280; COPOLYMER; GLUCOSE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; HPMA COPOLYMER PLATINATE; HPMA COPOLYMER-PLATINATE; NEW DRUG; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PLATINUM; PLATINUM COMPLEX; POLYMER;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; DRUG FORMULATION; DRUG INFUSION; DRUG STABILITY; DRUG STRUCTURE; HEMOLYSIS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; DRUG PACKAGING; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INFUSION PUMP; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUTION AND SOLUBILITY;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DIETHYLHEXYL PHTHALATE; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; DRUGS, INVESTIGATIONAL; HEMOLYSIS; HUMANS; INFUSION PUMPS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; PLATINUM; POLYMERS; SOLUTIONS;

EID: 0036812276     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200210000-00003     Document Type: Article

References (28)

1. Duncan R. Drug-polymer conjugates: Potential for improved drug chemotherapy. Anti-Cancer Drugs 1992; 3: 175-210.
2. Kopeçek J, Kopeçekova P, Minko T, Lu Z-R. HPMA copolymer-anticancer conjugates: Design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50: 61-81.
3. Matsamura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res 1986; 46: 6387-92.
4. Maeda H, Wu J, Sawa T, Matsamura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Contr Rel 2000; 65: 271-84.
5. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R. HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999; 33: 994-1002.
6. Rice JR, Stewart DR, Safai R, Howell SB, Nowotnik DR. Preclinical studies of the antitumor activity of AP 5280, a new polymer-linked platinum chemo-therapeutic agent. 2001 AACR/NCI/EORTC Int Conf, abstr 113 (available at http://www.aacr.org).
7. Rademaker-Lakhai JM, Terret C, Howell SB, et al. A phase I study of AP 5280, an HPMA copolymer-linked platinum therapeutic. Proc Am Soc Clin Oncol 2001; 21: 107a (abstr 425).
8. van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids. Fres J Anal Chem 1995; 351: 1820-4.
9. Nuijen B, Bouma M, Henrar REC, Manada C, Bult A, Beijnen JH. Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices and its hemolytic and precipitation potential upon intravenous administration. Anti-Cancer Drugs 1999; 10: 879-87.
10. Ward GH, Yalkowsky SH. Studies in phlebitis V: Hemolysis as a model for phlebitis. J Parenter Sci Technol 1993; 47: 44-6.
11. Krzyzaniak JF, Alvarez Núñez FA, Raymond DM, Yalkowsky SH. Lysis of human blood cells. 4. Comparison of in vitro and in vivo hemolysis data. J Pharm Sci 1997; 86: 1215-7.
12. Krzyzaniak JF, Raymond DM, Yalkowsky SH. Lysis of human blood cells. 2. Effect of contact time on cosolvent induced hemolysis. Int J Pharm 1997; 152: 193-200.
13. Krzyzaniak JF, Yalkowsky SH. Lysis of human blood cells. 3. Effect of contact time on surfactant-induced hemolysis. J Pharm Sci Technol 1998; 52: 66-9.
14. Trissel LA. Handbook on Injectable Drugs, 11th Edn. Bethesda, MD: American Society of Health-System Pharmacists 2001.
15. Parfitt K, ed. Martindale, the Complete Drug Reference, 32nd Edn. London: Pharmaceutical Press 1999.
16. Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987; 44: 124-30.
17. Lévi F, Metzger G, Massari C, Milano G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38: 1-21.
18. Product Information Eloxatin®. Sanofi-Synthelabo. Available at: www.sanofi-synthelabo.com.au/pdf/eloxatin-pi-pdf
19. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520-4.
20. Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm 1997; 54: 566-9.
21. Pearson SD, Trissel LA. Leaching of diethylhexyl phtalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993; 50: 1405-9.
22. Petrick RJ, Loucas SP, Cohl JK, Mehl B. Review of current knowledge of plastic intravenous fluid containers. Am J Hosp Pham 1997; 34: 357-62.
23. Elcombe ER, Mitchell AM. Peroxisome proliferation due to di(2-ethylhexyl) phtalate (DEHP): Species differences and possible mechanisms. Environ Health Perspect 1986; 70: 211-9.
24. Krzyzaniak JF, Yalkowsky SH. In vitro methods for evaluating intravascular hemolysis. In: Gupta PK, Brazeau GA, eds. Injectable Drug Development: Techniques to Reduce Pain and Irritation. Denver, CO: Interpharm Press 1999: 77-89.
25. Williams RJ. The surface activity of PVP and other polymers and their antihemolytic capacity. Cryobiology 1983; 20: 521-6.
26. Richardson S, Ferruti P, Duncan R. Poly(amido-amine)s as potential endosomolytic polymers: Evaluation in vitro and body distribution in normal and tumour-bearing animals. J Drug Targeting 1999; 6: 391-404.
27. Richardson Jr RR, Miller JA, Reichert WM. Polyimides as biomaterials, preliminary biocompatibility testing. Biomaterials 1993; 14: 627-35.
28. Dillingham EO, Webb N, Lawrence H, Autian J. Biological evaluation of polymers I. Poly-(methyl methacrylate). J Biomed Mater Res 1975; 9: 569-96.